If the risk of mass delistings is as real as some claim, with the obvious implications for patients, then surely it needs to be part of any forum hosted by or even involving the industry?
Surely the best 'patient view' is one that is fully informed?
September 2, 2022 Latest NewsBioPharmaComment
Latest Video
New Stories
-
Liberty expands into Asia Pacific life sciences insurance with new tailored offering
March 25, 2026 - - Australian Biotech -
PBAC agenda reflects increasing number of companies seeking revised recommendations
March 25, 2026 - - Latest News -
Faster FDA pathway approves new higher dose weight loss therapy in just 54 days
March 25, 2026 - - Latest News -
Australia moves closer to Europe as health and research ties deepen under landmark agreement
March 25, 2026 - - Latest News -
Small changes can still become foundations for the meaningful, but understand how decisions are made
March 25, 2026 - - Latest News -
Auditor General proposes possible reviews of new Centre for Disease Control
March 24, 2026 - - Latest News -
Radiopharm reports strong interim results for brain metastases imaging agent
March 24, 2026 - - Australian Biotech
